IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year Low - Should You Sell?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report)'s share price reached a new 52-week low on Friday . The company traded as low as $23.98 and last traded at $24.43, with a volume of 25948 shares. The stock had previously closed at $24.85.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on IDYA shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Leerink Partnrs lowered IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 5th. Leerink Partners lowered shares of IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $41.00 to $27.00 in a research report on Tuesday, November 5th. Stephens started coverage on shares of IDEAYA Biosciences in a report on Monday, November 18th. They issued an "overweight" rating and a $51.00 price target on the stock. Finally, Oppenheimer reiterated an "outperform" rating and set a $53.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $53.67.

IDEAYA Biosciences Stock Down 3.3 %

The stock has a market cap of $2.08 billion, a PE ratio of -10.31 and a beta of 0.82. The stock has a 50-day moving average of $26.89 and a 200 day moving average of $32.68.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same quarter in the previous year, the company earned ($0.46) earnings per share. On average, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -2.45 EPS for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of institutional investors have recently modified their holdings of IDYA. FMR LLC increased its holdings in shares of IDEAYA Biosciences by 12.1% during the 3rd quarter. FMR LLC now owns 12,635,653 shares of the company's stock valued at $400,297,000 after purchasing an additional 1,365,570 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of IDEAYA Biosciences during the third quarter worth approximately $42,681,000. Janus Henderson Group PLC raised its stake in IDEAYA Biosciences by 26.7% in the 3rd quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company's stock valued at $163,518,000 after purchasing an additional 1,086,356 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of IDEAYA Biosciences by 136.6% in the third quarter. Jennison Associates LLC now owns 972,266 shares of the company's stock worth $30,801,000 after buying an additional 561,404 shares in the last quarter. Finally, State Street Corp lifted its stake in IDEAYA Biosciences by 15.4% in the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company's stock worth $105,112,000 after purchasing an additional 443,640 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.